MLI Certified

On-Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies / Activity 1
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in metastatic NSCLC (mNSCLC) and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 2 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice to apply the evidence to real-world patient cases!
The Nine Elements to Experience a Good and Peaceful Death
Evolving the conversation with your patients from “I’m sorry you are going to die” to “Let me help you experience a good and peaceful death”. This video will demonstrate how to clearly communicate the nine evidence-based elements to a good and peaceful death and how to structure that conversation with your patient. What you will learn from this module: No matter what someone’s eventual cause of death will be, including our own, people will benefit from learning the 9 elements and how to achieve them. The timing of when to have such a discussion with a patient with advanced cancer very much influences her willingness to listen to her oncology specialist/provider of care, and be ready to embark on fulfilling these 9 elements. There is benefit in being able to tell a patient that you, her doctor, has already completed these 9 elements for yourself, demonstrating that they are appropriate for everyone, no matter their current health status. By doing so, it doesn’t cause the patient to feel that they have to complete it because they are dying. Patients all have different personal psychosocial experiences over their lifetime and these experiences and relationship with family and others influences how they approach each of these elements and complete them. Fulfilling these 9 elements cannot be achieved in a few days. This is why it is important to have this discussion in advance of a patient literally approaching end of life. Patients may need as much as 2 months to complete all of these elements, each one taking a different length of time. Helping patients learn about the 9 elements and making it an assignment for them to complete is a way to give patients something they can control during a time that they feel they cannot control anything. Some answers to these 9 elements will be surprising to you, and will provide you greater insight into your patients’ psychosocial history and current needs. You as the patient’s provider of care should launch the discussion about the 9 elements however there is no expectation that you need to help the patient literally think about each one with you and provide the answers. It is also okay to delegate someone like a nurse navigator, psyche nurse from your oncology team, social worker, or therapist to review in detail with the patient each element. Each element carries its own weight in the eyes of the patient. Some elements may be considered by her to be the most important ones to her where another patient identifies totally different ones that she sees as major. Making sure however that legal and financial affairs are in order is critical for everyone, including ourselves, and should be prioritized as such.
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
The Value and Importance of Not Postponing Joy
Educating your advanced cancer patients about the value and importance of not postponing joy. There is a tendency to avoid discussing the future, too far in advance, with your patients with advanced disease. The sooner we bring up the topic of not postponing joy, the better however. Patients may even say that they are planning on a family vacation to Disney World in 2 years. Your thoughts immediately go to estimating when she will be likely too ill to go but may not be verbalizing this to her. You don’t want to take away hope and burst that bubble. It however isn’t fair to the patient to be assuming that no response from you regarding such an announcement, or worse, saying that this sounds great, is doing her an injustice. Additionally, though she may still be living in two years and technically able to go to Disney World, she may very well be spending her time in the hotel room and not enjoying herself and her children/grandchildren doing park activities. Her goal wasn’t to be in a bed too weak to partake of this important family adventure. This is why a discussion about “Don’t Postpone Joy” is so important. It fits for many clinical settings too.
Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma
In this fourth episode, “Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty as they discuss the benefit of immune checkpoint inhibition for the treatment of HL in patients with relapsed/refractory disease. Discussions will also circulate around how interdisciplinary teams can assist with coordination of patient care, including clinical trials and access to appropriate treatment for those in underrepresented communities.
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - The Interconnection of OSA and Disease-related Complications
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape.
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
In on-demand activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty, Jeanne Palmer, MD and Jennifer Andres, APRN, FNP, MSN as they discuss Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) can optimize clinical outcomes and patient quality of life (QOL). Gain expert insights from enduring online program focuses on patient risk and drug mechanisms of action for effective treatment and management, gaps in MF care that influence patient QOL, disease- and treatment-related adverse events, trust with patients to improve outcomes and QOL, as well as shared decision-making and the unique role of multidisciplinary teams.
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Improving Collaboration Amongst Multidisciplinary Teams to Tackle OSA
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape.
Understanding the Impact of Weight on T2D Outcomes
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
In this combined enduring and live ONS chapter meeting activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) optimize clinical outcomes by improving overall patient quality of life (QOL). Learners will first participate in an enduring online program on the following topics: patient risk and drug mechanisms of action for effective treatment and management, gaps in MF care that influence patient QOL, disease- and treatment-related adverse events, trust with patients to improve outcomes and QOL, shared decision-making and the unique role of multidisciplinary teams. After completion of the enduring program, learners will have the opportunity to network with expert faculty at select live ONS chapter meetings at which time they will discuss various case studies regarding treatment selection and patient QOL. Learners will also participate in discussion questions and have time for one-on-one interaction with faculty and others nursing professionals.
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.
The Importance of Being Honest
Of everything we do for our patients, the most important thing we can give them is honesty. What you will learn from this module: Learn that being honest with patients about their disease and its prognosis is very important for patients to know so they can plan out the remainder of their lives. Honesty doesn’t take away hope; it helps the patient move through phases of hope. 50% of the time, doctors do not disclose the patients’ actual prognosis. Patients do not understand or know the difference between palliative chemotherapy and active chemotherapy treatments, unless they are told.  Teaching patients to be optimistic for as long as it is realistic, while having an end of life plan in place should be our mantra. Avoidance of honesty may be linked to an oncologist’s feelings of believing they have failed the patient by not being able to save or sustain their life.
The Evolution of HCT, Part 5: Shared Care
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 5 in a 5-part series, exploring how shared and coordinated care between transplant centers and hematology/oncology practices can help overcome barriers to HCT and improve patient outcomes and experience.
Overcoming Obesity: A PCP's Guide to Comprehensive Obesity Care
Addressing obesity in primary care remains a significant challenge, despite established evidence-based strategies and the introduction of new anti-obesity medications. Obstacles such as weight bias, stigma, and limited patient engagement in shared decision-making complicate effective weight management. With the growing array of therapeutic options for obesity, it is crucial for clinicians to adopt shared decision-making practices to improve treatment adherence, support patient goals, and foster holistic, patient-centered care. Join our engaging 3-part on-demand Community Collective Chapter Series, Overcoming Obesity: A PCP’s Guide to Comprehensive Obesity Care. This series, in collaboration with local AAFP Chapter meetings, equips learners with evidence-based approaches to screening, diagnosing, and treating obesity. Gain practical strategies for initiating weight management conversations with patients, incorporating shared decision-making to personalize treatment goals. Don’t miss this opportunity! Enroll now to gain valuable insights and elevate your practice in obesity care.
Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies
In this second episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty on how to select CAR T-cell and bispecific antibody treatment regimens for NHL according to the latest clinical evidence including safety and efficacy data in accordance with clinical guidelines. Additionally, expert faculty will discuss how to best identify patients who are candidates for CAR T-cell or bispecific antibody therapies as well as how to evaluate the potential of bridging therapy in patients awaiting CAR T-cell therapy. Finally, expert faculty will review treatment-related toxicities with strategies and educational tools that can be used to prevent, monitor, and manage adverse events. This episode will conclude with a discussion between expert faculty and a special guest, Caitlin Murphy, DNP.
The Evolution of HCT, Part 4: Addressing Barriers
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 4 in a 5-part series, examining major barriers to HCT and ways to overcome them.
Weight Management as a Treatment for T2D: Novel Pharmacological Approaches
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
The Burden of Vaccine-Preventable Disease: Assessing Risk in Older Adults
Healthcare providers (HCPs) encounter significant challenges in vaccine acceptance. A critical need exists among primary care providers (PCPs) to remain abreast of the continuously evolving vaccination landscape. As such, PCPs need to be able to evaluate the burden of vaccine-preventable diseases, provide well-founded recommendations for vaccine measures, and apply appropriate strategies to address vaccine hesitations.
DIABESITY DIALOGUES:Beyond Inertia: Advancing T2D Care With Innovative Basal Insulin Strategies
Discover the forefront of diabetes care at Diabetes Dialogues LIVE, targeting the latest in once-weekly basal insulin therapy, including unique mechanism of action and pharmacokinetic/pharmacodynamic properties. Join fellow endocrinologists to unpack recent safety and efficacy data. Additionally, hear discussion about basal insulin therapy for patient care and how to best ensure adherence through effective T2D management. Delve into clinical trials outcomes, glycemic control, weight management, and hypoglycemia risks. Engage in essential scientific discourse to shape the future of diabetes treatment. Do not miss this event for an insightful blend of data and practice. This activity is derived from the Live ISS Meeting at ENDO, originally held on June 1, 2024.
Shared Decision Making
It is a process that fosters shared decision making that includes exploring and comparing the benefits, harms, and risks of each health care option through meaningful dialogue about what matters most to the patient. The doctor and patient need to use evidence-based information while working together to make the best possible treatment decisions.
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!
Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients
Treatment for R/R MCL is complicated, as the disease typically presents in elderly, unfit patients; however, emerging targeted therapy options have shown great promise based on excellent results in clinical trials. In this activity, a taped version of the live symposium at the 17th Annual International Conference on Malignant Lymphoma, expert faculty present therapeutic options, established by evidence-based practice guidelines, for patients with R/R MCL. Symposium learners voted on patient demographics and parameters such as treatment, dosing frequency, and adverse events. The experts crafted their lecture to follow thheir suggestions allowing the case studies to reflect the patients the learners see. The activity concludes with a discussion on engagement between healthcare providers and patients to improve clinical outcomes.
The Evolution of HCT, Part 3: Donor Availability
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
Setting Up Patients for HCT and Cell Therapy Success
This self-guided course provides practical recommendations and guidance on what hematology/oncology practices can do to improve patient experience and outcomes before their patient reaches a transplant center for consultation for Hematopoietic Cell Transplantation (HCT).
Scroll to Top